Stop Renting Site Intelligence. Start Building Institutional Memory.
Pharma, biotech, and CROs keep renting the same ClinOps benchmarks everyone else has, while throwing away the one asset no competitor can buy: their own operational memory.
Trials & Triumphs
On the relentless pursuit of human progress at the intersection of scientific breakthroughs and the operational reality holding it back.
Live Last read · last published · next check
Latest posts
Why CROs Lose Bids They Should Win
Notes from three months reading what CROs send to sponsors
Should My Daughter Be the Centre of My World, or a Witness to It?
Lily just turned 10 today. On motherhood as an evolutionary role and a social identity.
Why Pharma and Biotech Struggle to Choose the Right CRO
Most pharma and biotech pre-award questionnaires are not designed to support good CRO selection.
Teaching children agency in the age of AI
Today I taught my first coding class to six children between 8 and 12 years old at Yendou.
Why is anything important?
A few weeks ago I was asked why I want Eroom’s law to be crushed.
Why We Decided To Build For CROs First
I was having a conversation with a tech company in the site identification and selection space, and they were surprised that we do not sell to pharma: that we had decided Yendou is a CRO vendor.
Against Regulations. My TED Talk
Hey!
Is Single Sign-On really what sites need?
Whatever the problem sites have, Single Sign-On won’t fix it.
Platform Trials as a Service: A CRO Model for Rare Diseases?
In the mid-1990s, Ford spent four years building the new Taurus.